Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Change in Cash (2016 - 2025)

Historic Change in Cash for Lexaria Bioscience (LEXX) over the last 15 years, with Q4 2025 value amounting to $2.5 million.

  • Lexaria Bioscience's Change in Cash rose 5706.78% to $2.5 million in Q4 2025 from the same period last year, while for Nov 2025 it was -$3.8 million, marking a year-over-year decrease of 16200.14%. This contributed to the annual value of -$4.7 million for FY2025, which is 19125.8% down from last year.
  • According to the latest figures from Q4 2025, Lexaria Bioscience's Change in Cash is $2.5 million, which was up 5706.78% from -$2.8 million recorded in Q3 2025.
  • In the past 5 years, Lexaria Bioscience's Change in Cash registered a high of $8.8 million during Q1 2021, and its lowest value of -$2.8 million during Q3 2025.
  • In the last 5 years, Lexaria Bioscience's Change in Cash had a median value of -$1.2 million in 2021 and averaged $187794.6.
  • In the last 5 years, Lexaria Bioscience's Change in Cash tumbled by 19570.29% in 2021 and then surged by 356933.53% in 2024.
  • Quarter analysis of 5 years shows Lexaria Bioscience's Change in Cash stood at -$1.2 million in 2021, then dropped by 3.61% to -$1.3 million in 2022, then skyrocketed by 147.03% to $602063.0 in 2023, then skyrocketed by 162.16% to $1.6 million in 2024, then surged by 57.07% to $2.5 million in 2025.
  • Its last three reported values are $2.5 million in Q4 2025, -$2.8 million for Q3 2025, and -$1.9 million during Q2 2025.